Avadel Pharmaceuticals (AVDL) Competitors $15.41 +0.22 (+1.45%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$15.32 -0.10 (-0.62%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, and ADMAShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Its Competitors Nuvalent TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Nuvalent (NASDAQ:NUVL) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership. Do analysts recommend NUVL or AVDL? Nuvalent presently has a consensus target price of $119.50, suggesting a potential upside of 52.56%. Avadel Pharmaceuticals has a consensus target price of $20.86, suggesting a potential upside of 35.35%. Given Nuvalent's higher probable upside, analysts plainly believe Nuvalent is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Avadel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 Is NUVL or AVDL more profitable? Nuvalent has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Avadel Pharmaceuticals -1.32%-3.73%-1.73% Which has more volatility and risk, NUVL or AVDL? Nuvalent has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Does the media favor NUVL or AVDL? In the previous week, Nuvalent and Nuvalent both had 7 articles in the media. Avadel Pharmaceuticals' average media sentiment score of 1.37 beat Nuvalent's score of 1.04 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of NUVL or AVDL? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, NUVL or AVDL? Avadel Pharmaceuticals has higher revenue and earnings than Nuvalent. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.99Avadel Pharmaceuticals$169.12M8.85-$48.83M-$0.03-513.67 SummaryAvadel Pharmaceuticals beats Nuvalent on 9 of the 15 factors compared between the two stocks. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-513.6723.4976.3926.51Price / Sales8.85672.77527.15123.58Price / CashN/A169.4937.1760.46Price / Book20.015.3313.306.29Net Income-$48.83M$32.95M$3.28B$270.51M7 Day Performance-2.53%0.10%0.88%1.95%1 Month Performance12.56%3.91%4.67%6.33%1 Year Performance11.42%-3.91%76.59%25.62% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals3.0938 of 5 stars$15.41+1.4%$20.86+35.3%+11.6%$1.47B$169.12M-513.6770NUVLNuvalent3.1563 of 5 stars$79.83-1.3%$120.91+51.5%-30.2%$5.83BN/A0.0040Positive NewsTGTXTG Therapeutics4.2984 of 5 stars$32.38+0.5%$46.25+42.8%+28.5%$5.11B$329M87.51290Positive NewsMRUSMerus2.7802 of 5 stars$67.19-0.4%$88.75+32.1%+33.3%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.0867 of 5 stars$54.10-1.4%$71.60+32.3%+28.2%$4.99B$37.31M0.00460PTCTPTC Therapeutics3.7281 of 5 stars$56.95-0.5%$69.00+21.2%+76.8%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9509 of 5 stars$145.20-3.4%$210.38+44.9%-20.5%$4.35B$290.52M30.54210News CoveragePositive NewsAnalyst ForecastPCVXVaxcyte2.1798 of 5 stars$32.41-1.8%$130.00+301.1%-72.7%$4.29BN/A0.00160Positive NewsACADACADIA Pharmaceuticals4.3303 of 5 stars$25.39+0.5%$28.88+13.7%+48.5%$4.26B$957.80M19.09510ACLXArcellx2.097 of 5 stars$71.11-2.1%$114.31+60.7%+0.4%$4.03B$107.94M0.0080Positive NewsADMAADMA Biologics3.4882 of 5 stars$16.42-2.7%$27.67+68.5%-13.8%$4.03B$426.45M19.09530Positive News Related Companies and Tools Related Companies NUVL Competitors TGTX Competitors MRUS Competitors CRSP Competitors PTCT Competitors KRYS Competitors PCVX Competitors ACAD Competitors ACLX Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVDL Stock Alerts